title: [Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment].
abstract: The clinical outcomes, including adverse events, in 34 unresectable advanced colorectal cancer patients with wild-type K-ras, who were treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment, were analyzed for confirmation of the effectiveness and safety of this treatment. The response rate of the patients was 44% (complete remission, 2 patients; and partial remission, 13 patients). The median progression-free survival and overall survival in these patients was 11.1 and 25.1 months, respectively. Adverse events of greater than grade 3 were observed in 18 patients. Of these patients, 10 exhibited grade 3/4 neutropenia, and 6 had peripheral neuropathy. Our results were similar to those of randomized phase III trials from abroad, including those using anti-epidermal growth factor receptor antibody, with respect to effectiveness and safety. Furthermore, patients with liver metastasis had poor prognosis compared to those with metastasis to organs other than the liver. Further analysis will be required to better understand these results.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical University, Japan.
authors.forename: Hideko
authors.initials: H
authors.lastname: Imaizumi
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tajima
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Amano
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hatano
authors.forename: Kouki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Jun
authors.initials: J
authors.lastname: Sobajima
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kumagai
authors.forename: Norihiro
authors.initials: N
authors.lastname: Haga
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D016283:Proto-Oncogene Proteins p21(ras)